Chronic Musculoskeletal PainvEAET-HNCT07732062
vEAET-H for Chronic Pain Patients Using Medical Cannabis in Israel - A Feasibility Study
A study testing Group-based virtual Emotional Awareness & Expression Therapy - Hebrew (vEAET-H) in people with Chronic Musculoskeletal Pain and Cannabis Use, run by Reuth Rehabilitation Hospital at 1 site in Israel.
Trial summary
The goal of this clinical trial is to evaluate whether a culturally adapted, virtual, group-based emotional therapy called Emotional Awareness and Expression Therapy is feasible and whether it can help reduce chronic pain and improve emotional well-being among Israeli adults who suffer from chronic musculoskeletal… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Chronic Musculoskeletal Pain, Cannabis Use
- What is being tested?
- Group-based virtual Emotional Awareness & Expression Therapy - Hebrew (vEAET-H)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 42 participants
- Where
- 1 siteIsrael
- Study dates
- 1 Oct 2026to 1 Oct 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosed with any chronic musculoskeletal pain (≥ three months in duration) including back, neck, limb or pelvic pain, tension headache and fibromyalgia;
- Treated with medical Cannabis;
- Physical and mental ability to participate in group discussions;
- Fluent in reading and speaking Hebrew.
Who cannot join
- Chronic pain conditions not classified as chronic primary pain. These include neuropathies such as carpal or tarsal tunnel syndrome, radiculopathy, and neuralgia;
- Primary headache disorders such as cluster headaches;
- Cancer-related pain;
- Burn- or infection-related chronic pain;
- Autoimmune diseases typically associated with pain, including rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, systemic lupus erythematosus, and sickle cell disease;
- Inflammatory systemic diseases causing pain, including osteoarthritis or gout.
Show all 9Show fewer
- Severe mental illness or psychiatric disorder such as schizophrenia, bipolar I disorder, multiple personality disorder, or dissociative identity disorder not controlled with medications, active suicide or violence risk in the past year, active severe alcohol or substance use disorder, self-reported use of intravenous drugs.
- Participant with a significant negative life event within the past six months, such as the death of a close person, significant loss of income, or another traumatic or highly stressful event, which may substantially affect the participant's emotional state, safety, or ability to participate in the intervention;
- Current participation in another psychological or behavioral therapy, program, or clinical study.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Pnina Marom, M.P.H.; Ph.D. Student contact
Israel1 site, 1 recruiting
- Recruiting
Reuth Rehabilitation Hospital
Tel Aviv, 6772830
Keren Sivan-Speier, M.D, +972-732701610, keren.sivan@reuth.org.il
About this study
Official title: A Group-Based, Virtual Emotional Awareness and Expression Therapy Intervention - Hebrew (EAET-H) for Chronic Pain Patients Treated With Medical Cannabis in Israel - A Feasibility Study
The goal of this clinical trial is to evaluate whether a culturally adapted, virtual, group-based emotional therapy called Emotional Awareness and Expression Therapy is feasible and whether it can help reduce chronic pain and improve emotional well-being among Israeli adults who suffer from chronic musculoskeletal pain and are treated with medical cannabis.
Participants will attend a weekly 1.5-hour virtual group therapy session for 8 weeks, except for the first session, which will be held in-person at the hospital's clinic. The participants will take part in group discussions and emotional processing exercises, complete questionnaires about pain levels, mood, sleep, and quality of life, and continue their usual medical treatment as prescribed by their doctors.
Read the detailed description
The rising prevalence of chronic pain conditions poses a significant challenge to societies and healthcare systems globally. Despite medical advancements, many individuals continue to face chronic pain daily, with only limited success in alleviating pain and enhancing physical and emotional well-being. Faced with these challenges, numerous individuals with chronic pain have experimented with medical cannabis as an alternative form of pain management. Furthermore, the psychological burden associated with chronic pain highlights the critical need for integrating psychological support within chronic pain treatment strategies.
Emotional Awareness and Expression Therapy (EAET) has demonstrated considerable reductions in pain and improvements in psychological conditions such as depression and anxiety among adults with various types of chronic pain. However, the EAET intervention has never been tested in patients treated with medical cannabis and has not yet been evaluated in Israel. Our preliminary pilot trial culturally adapted the EAET protocol into Hebrew and evaluated it in a face-to-face format. In the subsequent phase, the program will be delivered in a virtual format, rather than in person, based on insights derived from the pilot study.
This study aims to assess the feasibility, acceptability, and preliminary efficacy of a culturally adapted, eight-session, group-based virtual EAET-Hebrew intervention through a feasibility trial. The primary outcome is pain severity. The secondary outcome measures that will be assessed in this study are: pain interference and disability, pain catastrophizing, fear and pain beliefs, mood and satisfaction with life, physical functioning and quality of life, sleep and fatigue, global impression of change, health service utilization, and cannabis consumption.
Description of the intervention: An innovative psychological treatment, EAET is a psychotherapeutic approach that emphasizes the role of emotional processing of unresolved trauma, stress, and conflict in the treatment of chronic pain and somatic symptoms. The intervention will be delivered as a 1.5-hour virtual weekly group session over a period of 8 weeks, although the first session will be held in-person at the hospital's clinic. Each session will include two parts, theoretical and practical, and will combine group discussion and the sharing of experiences.
The study will take place at "Reuth" Rehabilitation Hospital, Tel Aviv. Patients with chronic musculoskeletal pain who are also medical cannabis consumers and are treated at the pain and cannabis clinics will be recruited for the study.
Following completion of this research, a well-defined protocol for a virtual group-based EAET program in Hebrew will be developed, tailored to the Israeli context with culture-specific norms and beliefs to meet patients' unique needs effectively. This research aims to provide clear insights into the feasibility and preliminary efficacy of the adapted program through a rigorous feasibility pilot trial. This step marks the first instance in which this innovative approach, found to be superior to traditional cognitive-behavioural therapy treatments, is tested among pain patients who are treated with medical cannabis and in Israel.
It is expected to reduce pain levels and disability while alleviating the mental strain experienced by patients, areas that are currently inadequately addressed. The anticipated result is a major advancement in the existing chronic pain treatment paradigm in Israel, incorporating a significant psychological component and capitalizing on the benefits of group therapy in a virtual format that is accessible to patients.
- Conditions
- Chronic Musculoskeletal Pain, Cannabis Use
- Being tested
- Group-based virtual Emotional Awareness & Expression Therapy - Hebrew (vEAET-H)
- Keywords
- Chronic musculoskeletal pain, Cannabis Use, Emotional Awareness and Expression Therapy, Emotional Therapy, Psychological Therapy, Group-Based, telehealth
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Group-based virtual Emotional Awareness & Expression Therapy - Hebrew (vEAET-H)Other
This study will use the culturally adapted, eight-session, group-based EAET manual, originally developed by Mark A. Lumley and Howard Schubiner, in an online format. However, the first session will be held in-person at the hospital's clinic. Several adaptations to this manual were made: a) translation of the manual into Hebrew; b) adaptations to the Israeli context and setting; and c) the manual's language was changed from "fibromyalgia" to "chronic pain," and adaptations were made accordingly. Group participants will receive a class syllabus and an educational booklet for the vEAET-H program.
| Study group | Role | What they receive |
|---|---|---|
| Group-based vEAET-H | Experimental | Group-based Virtual Emotional Awareness \& Expression Therapy - Hebrew Receives: Other: Group-based virtual Emotional Awareness & Expression Therapy - Hebrew (vEAET-H) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Brief Pain Inventory (BPI) - 4 items of pain severity
The Brief Pain Inventory (BPI) pain severity subscale is a self-report measure comprising four items that assess pain intensity at its worst, least, average, and current levels. Each item is rated on a 10-point numerical rating scale ranging from 0 ("no pain") to 10 ("pain as bad as you can imagine"). The overall pain severity score is calculated as the mean of the four items and ranges from 0 to 10, with higher scores indicating greater pain severity and therefore a worse outcome.
Measured: Pre-intervention (baseline), post-intervention (8 weeks after baseline), and follow-up (one month post-intervention)
Secondary outcomes (12)
Brief Pain Inventory (BPI) - 7 items of pain interference
The Brief Pain Inventory (BPI) pain interference subscale is a self-report measure used to assess the extent to which pain interferes with daily functioning. It comprises seven items assessing general activity, mood, walking ability, normal work, relations with others, sleep, and enjoyment of life. Each item is rated on an 11-point numerical rating scale ranging from 0 ("does not interfere") to 10 ("completely interferes"). The overall pain interference score is calculated as the mean of the seven items and ranges from 0 to 10, with higher scores indicating greater pain-related interference and therefore a worse outcome.
Measured: Pre-intervention (baseline), post-intervention (8 weeks after baseline), and follow-up (one month post-intervention)
The Hospital Anxiety and Depression Scale (HADS)
The Hospital Anxiety and Depression Scale (HADS) is a 14-item self-report questionnaire designed to assess symptoms of anxiety and depression in non-psychiatric hospital populations. It comprises two seven-item subscales: the Hospital Anxiety and Depression Scale-Anxiety subscale (HADS-A) and the Hospital Anxiety and Depression Scale-Depression subscale (HADS-D). Each item is rated on a 4-point scale ranging from 0 to 3. Scores for each subscale are calculated by summing the seven corresponding items and range from 0 to 21, with higher scores indicating greater anxiety or depressive symptom severity and therefore a worse outcome.
Measured: Pre-intervention (baseline), post-intervention (8 weeks after baseline), and follow-up (one month post-intervention)
Pain Self-Efficacy Questionnaire (PSEQ)
The Pain Self-Efficacy Questionnaire (PSEQ) is a 10-item self-report measure designed to assess individuals' confidence in performing daily activities despite chronic pain. Each item is rated on a 7-point scale ranging from 0 ("not at all confident") to 6 ("completely confident"). Item scores are summed to produce a total score ranging from 0 to 60, with higher scores indicating greater pain self-efficacy and therefore a better outcome.
Measured: Pre-intervention (baseline), post-intervention (8 weeks after baseline), and follow-up (one month post-intervention)
Pain Catastrophizing Scale (PCS)
The Pain Catastrophizing Scale (PCS) is a 13-item self-report questionnaire designed to assess negative thoughts and feelings related to pain. It comprises three subscales: rumination, magnification, and helplessness. Each item is rated on a 5-point scale ranging from 0 ("not at all") to 4 ("all the time"). Item scores are summed to produce a total score ranging from 0 to 52, with higher scores indicating greater pain catastrophizing and therefore a worse outcome.
Measured: Pre-intervention (baseline), post-intervention (8 weeks after baseline), and follow-up (one month post-intervention)
Fear-Avoidance Beliefs Questionnaire (FABQ)
The Fear-Avoidance Beliefs Questionnaire (FABQ) is a 16-item self-report measure designed to assess beliefs about how physical activity and work may affect pain. Eleven items are included in the scoring of two subscales: the four-item Fear-Avoidance Beliefs Questionnaire-Physical Activity subscale (FABQ-PA) and the seven-item Fear-Avoidance Beliefs Questionnaire-Work subscale (FABQ-W). Each item is rated on a 7-point scale ranging from 0 ("completely disagree") to 6 ("completely agree"). Item scores are summed separately for each subscale. The FABQ-PA score ranges from 0 to 24, and the FABQ-W score ranges from 0 to 42. Higher scores indicate stronger fear-avoidance beliefs related to physical activity or work and therefore a worse outcome.
Measured: Pre-intervention (baseline), post-intervention (8 weeks after baseline), and follow-up (one month post-intervention)
The Satisfaction with Life Scale (SWLS)
The Satisfaction With Life Scale (SWLS) is a five-item self-report questionnaire designed to assess overall cognitive judgments of life satisfaction. Each item is rated on a 7-point scale ranging from 1 ("strongly disagree") to 7 ("strongly agree"). Item scores are summed to produce a total score ranging from 5 to 35, with higher scores indicating greater life satisfaction and therefore a better outcome.
Measured: Pre-intervention (baseline), post-intervention (8 weeks after baseline), and follow-up (one month post-intervention)
Toronto Alexithymia Scale (TAS)
The 20-Item Toronto Alexithymia Scale (TAS-20) is a self-report questionnaire designed to assess alexithymia-related traits across three dimensions: difficulty identifying feelings, difficulty describing feelings, and externally oriented thinking. Each item is rated on a 5-point scale ranging from 1 ("strongly disagree") to 5 ("strongly agree"). After reverse-scoring the relevant items, item scores are summed to produce a total score ranging from 20 to 100, with higher scores indicating greater levels of alexithymia and therefore a worse outcome.
Measured: Pre-intervention (baseline), post-intervention (8 weeks after baseline), and follow-up (one month post-intervention)
The Pittsburgh Sleep Quality Index (PSQI)
The Pittsburgh Sleep Quality Index (PSQI) is a 19-item self-report questionnaire designed to assess sleep quality and sleep disturbances over the previous month. The items are used to derive seven component scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. Each component is scored from 0 to 3, and the seven component scores are summed to produce a global score ranging from 0 to 21. Higher scores indicate poorer sleep quality and greater sleep disturbance and therefore a worse outcome.
Measured: Pre-intervention (baseline), post-intervention (8 weeks after baseline), and follow-up (one month post-intervention)
The Fatigue Severity Scale (FSS)
The Fatigue Severity Scale (FSS) is a nine-item self-report questionnaire designed to assess fatigue severity and its impact on motivation, physical activity, work, and daily functioning. Each item is rated on a 7-point scale ranging from 1 ("strongly disagree") to 7 ("strongly agree"). The overall score is calculated as the mean of the nine items and ranges from 1 to 7, with higher scores indicating greater fatigue severity and therefore a worse outcome.
Measured: Pre-intervention (baseline), post-intervention (8 weeks after baseline), and follow-up (one month post-intervention)
The Patient Global Impression of Change (PGIC)
The Patient Global Impression of Change (PGIC) is a single-item self-report measure designed to assess the participant's overall perceived change in their condition since the beginning of treatment. Participants rate their change on a 7-point scale ranging from 1 ("no change at all") to 7 ("very much improved"). Higher scores indicate greater perceived improvement.
Measured: Post-intervention (8 weeks after baseline), and follow-up (one month post-intervention)
Medical cannabis consumption
One question was developed specifically for this study to assess the frequency of cannabis use: "How frequently do you use cannabis during a typical week?"
Measured: Pre-intervention (baseline), post-intervention (8 weeks after baseline), and follow-up (one month post-intervention)
Health care use
Four questions were developed specifically for this study to assess participants' regular medication use, the types and frequency of treatments received, and the number of physician visits during the previous three months.
Measured: Pre-intervention (baseline), post-intervention (8 weeks after baseline), and follow-up (one month post-intervention)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Jul 2026
- Study start1 Oct 2026 (estimated)
- Primary completion1 Oct 2027 (estimated)
- Study completion1 Oct 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Chronic Musculoskeletal PainStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- A single-arm feasibility study
- Masking
- None (open label)
- Enrolment
- 42 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Reuth Rehabilitation Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Keren Sivan-Speier, M.D., Principal investigator, Reuth Rehabilitation Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07732062
- Sponsor's protocol ID
- 0017.1-21-RRH
- Acronym
- vEAET-H
- Status last verified
- Jul 2026
- First submitted
- 25 May 2026
- Last updated
- 28 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: IPD will be shared only with researchers on the study team and not with any individuals outside the team. Additionally, the data will be stored on the computers of the research institute at the hospital where the intervention program is being conducted.
Publications
Lumley MA, Schubiner H. Psychological Therapy for Centralized Pain: An Integrative Assessment and Treatment Model. Psychosom Med. 2019 Feb/Mar;81(2):114-124. doi: 10.1097/PSY.0000000000000654.
PubMed 30461545Lumley MA, Schubiner H. Emotional Awareness and Expression Therapy for Chronic Pain: Rationale, Principles and Techniques, Evidence, and Critical Review. Curr Rheumatol Rep. 2019 May 23;21(7):30. doi: 10.1007/s11926-019-0829-6.
PubMed 31123837
Study at a glance
From the registry record, last updated by the sponsor on 28 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Group-Based, Virtual Emotional Awareness and Expression Therapy Intervention - Hebrew (EAET-H) for Chronic Pain Patients Treated With Medical Cannabis in Israel - A Feasibility Study
- ClinicalTrials.gov ID
- NCT07732062
- Acronym / sponsor ID
- vEAET-H / 0017.1-21-RRH
- Conditions
- Chronic Musculoskeletal Pain, Cannabis Use
- Keywords
- Chronic musculoskeletal pain, Cannabis Use, Emotional Awareness and Expression Therapy, Emotional Therapy, Psychological Therapy, Group-Based, telehealth
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 42 participants (estimated)
- Lead sponsor
- Reuth Rehabilitation HospitalUniversity, hospital or other
- Study start
- 1 Oct 2026 (estimated)
- Primary completion
- 1 Oct 2027 (estimated)
- Study completion
- 1 Oct 2027 (estimated)
- First posted
- 28 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to evaluate whether a culturally adapted, virtual, group-based emotional therapy called Emotional Awareness and Expression Therapy is feasible and whether it can help reduce chronic pain and improve emotional well-being among Israeli adults who suffer from chronic musculoskeletal pain and are treated with medical cannabis.
Participants will attend a weekly 1.5-hour virtual group therapy session for 8 weeks, except for the first session, which will be held in-person at the hospital's clinic. The participants will take part in group discussions and emotional processing exercises, complete questionnaires about pain levels, mood, sleep, and quality of life, and continue their usual medical treatment as prescribed by their doctors.
Detailed description
The rising prevalence of chronic pain conditions poses a significant challenge to societies and healthcare systems globally. Despite medical advancements, many individuals continue to face chronic pain daily, with only limited success in alleviating pain and enhancing physical and emotional well-being. Faced with these challenges, numerous individuals with chronic pain have experimented with medical cannabis as an alternative form of pain management. Furthermore, the psychological burden associated with chronic pain highlights the critical need for integrating psychological support within chronic pain treatment strategies.
Emotional Awareness and Expression Therapy (EAET) has demonstrated considerable reductions in pain and improvements in psychological conditions such as depression and anxiety among adults with various types of chronic pain. However, the EAET intervention has never been tested in patients treated with medical cannabis and has not yet been evaluated in Israel. Our preliminary pilot trial culturally adapted the EAET protocol into Hebrew and evaluated it in a face-to-face format. In the subsequent phase, the program will be delivered in a virtual format, rather than in person, based on insights derived from the pilot study.
This study aims to assess the feasibility, acceptability, and preliminary efficacy of a culturally adapted, eight-session, group-based virtual EAET-Hebrew intervention through a feasibility trial. The primary outcome is pain severity. The secondary outcome measures that will be assessed in this study are: pain interference and disability, pain catastrophizing, fear and pain beliefs, mood and satisfaction with life, physical functioning and quality of life, sleep and fatigue, global impression of change, health service utilization, and cannabis consumption.
Description of the intervention: An innovative psychological treatment, EAET is a psychotherapeutic approach that emphasizes the role of emotional processing of unresolved trauma, stress, and conflict in the treatment of chronic pain and somatic symptoms. The intervention will be delivered as a 1.5-hour virtual weekly group session over a period of 8 weeks, although the first session will be held in-person at the hospital's clinic. Each session will include two parts, theoretical and practical, and will combine group discussion and the sharing of experiences.
The study will take place at "Reuth" Rehabilitation Hospital, Tel Aviv. Patients with chronic musculoskeletal pain who are also medical cannabis consumers and are treated at the pain and cannabis clinics will be recruited for the study.
Following completion of this research, a well-defined protocol for a virtual group-based EAET program in Hebrew will be developed, tailored to the Israeli context with culture-specific norms and beliefs to meet patients' unique needs effectively. This research aims to provide clear insights into the feasibility and preliminary efficacy of the adapted program through a rigorous feasibility pilot trial. This step marks the first instance in which this innovative approach, found to be superior to traditional cognitive-behavioural therapy treatments, is tested among pain patients who are treated with medical cannabis and in Israel.
It is expected to reduce pain levels and disability while alleviating the mental strain experienced by patients, areas that are currently inadequately addressed. The anticipated result is a major advancement in the existing chronic pain treatment paradigm in Israel, incorporating a significant psychological component and capitalizing on the benefits of group therapy in a virtual format that is accessible to patients.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- A single-arm feasibility study
| Arm | Type | Receives |
|---|---|---|
| Group-based vEAET-H | Experimental | Other: Group-based virtual Emotional Awareness & Expression Therapy - Hebrew (vEAET-H)Group-based Virtual Emotional Awareness \& Expression Therapy - Hebrew |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Diagnosed with any chronic musculoskeletal pain (≥ three months in duration) including back, neck, limb or pelvic pain, tension headache and fibromyalgia;
- Treated with medical Cannabis;
- Physical and mental ability to participate in group discussions;
- Fluent in reading and speaking Hebrew.
Key exclusion criteria (9 listed)
- Chronic pain conditions not classified as chronic primary pain. These include neuropathies such as carpal or tarsal tunnel syndrome, radiculopathy, and neuralgia;
- Primary headache disorders such as cluster headaches;
- Cancer-related pain;
- Burn- or infection-related chronic pain;
- Autoimmune diseases typically associated with pain, including rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, systemic lupus erythematosus, and sickle cell disease;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Group-based virtual Emotional Awareness & Expression Therapy - Hebrew (vEAET-H)This study will use the culturally adapted, eight-session, group-based EAET manual, originally developed by Mark A. Lumley and Howard Schubiner, in an online format. However, the first session will be held in-person at the hospital's clinic. Several adaptations to this manual were made: a) translation of the manual into Hebrew; b) adaptations to the Israeli context and setting; and c) the manual's language was changed from "fibromyalgia" to "chronic pain," and adaptations were made accordingly. Group participants will receive a class syllabus and an educational booklet for the vEAET-H program. | Other | Group-based vEAET-H |
Primary outcome
Brief Pain Inventory (BPI) - 4 items of pain severity
Time frame: Pre-intervention (baseline), post-intervention (8 weeks after baseline), and follow-up (one month post-intervention)
The Brief Pain Inventory (BPI) pain severity subscale is a self-report measure comprising four items that assess pain intensity at its worst, least, average, and current levels. Each item is rated on a 10-point numerical rating scale ranging from 0 ("no pain") to 10 ("pain as bad as you can imagine"). The overall pain severity score is calculated as the mean of the four items and ranges from 0 to 10, with higher scores indicating greater pain severity and therefore a worse outcome.
12 secondary outcomes
Brief Pain Inventory (BPI) - 7 items of pain interference
Time frame: Pre-intervention (baseline), post-intervention (8 weeks after baseline), and follow-up (one month post-intervention)
The Hospital Anxiety and Depression Scale (HADS)
Time frame: Pre-intervention (baseline), post-intervention (8 weeks after baseline), and follow-up (one month post-intervention)
Pain Self-Efficacy Questionnaire (PSEQ)
Time frame: Pre-intervention (baseline), post-intervention (8 weeks after baseline), and follow-up (one month post-intervention)
Pain Catastrophizing Scale (PCS)
Time frame: Pre-intervention (baseline), post-intervention (8 weeks after baseline), and follow-up (one month post-intervention)
Fear-Avoidance Beliefs Questionnaire (FABQ)
Time frame: Pre-intervention (baseline), post-intervention (8 weeks after baseline), and follow-up (one month post-intervention)
The Satisfaction with Life Scale (SWLS)
Time frame: Pre-intervention (baseline), post-intervention (8 weeks after baseline), and follow-up (one month post-intervention)
Toronto Alexithymia Scale (TAS)
Time frame: Pre-intervention (baseline), post-intervention (8 weeks after baseline), and follow-up (one month post-intervention)
The Pittsburgh Sleep Quality Index (PSQI)
Time frame: Pre-intervention (baseline), post-intervention (8 weeks after baseline), and follow-up (one month post-intervention)
The Fatigue Severity Scale (FSS)
Time frame: Pre-intervention (baseline), post-intervention (8 weeks after baseline), and follow-up (one month post-intervention)
The Patient Global Impression of Change (PGIC)
Time frame: Post-intervention (8 weeks after baseline), and follow-up (one month post-intervention)
Medical cannabis consumption
Time frame: Pre-intervention (baseline), post-intervention (8 weeks after baseline), and follow-up (one month post-intervention)
Health care use
Time frame: Pre-intervention (baseline), post-intervention (8 weeks after baseline), and follow-up (one month post-intervention)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Jul 2026.
- Background: PubMed 30461545Lumley MA, Schubiner H. Psychological Therapy for Centralized Pain: An Integrative Assessment and Treatment Model. Psychosom Med. 2019 Feb/Mar;81(2):114-124. doi: 10.1097/PSY.0000000000000654.
- Background: PubMed 31123837Lumley MA, Schubiner H. Emotional Awareness and Expression Therapy for Chronic Pain: Rationale, Principles and Techniques, Evidence, and Critical Review. Curr Rheumatol Rep. 2019 May 23;21(7):30. doi: 10.1007/s11926-019-0829-6.
- Individual participant dataSharing planned: No. IPD will be shared only with researchers on the study team and not with any individuals outside the team. Additionally, the data will be stored on the computers of the research institute at the hospital where the intervention program is being conducted.
Related trials for Chronic Musculoskeletal Pain
Recruiting
BioPoly® Partial Resurfacing Knee Implant IDE
Knee Pain Chronic, Knee Osteoarthritis
RecruitingPhase 4
PENG vs L-ESPB With S-ESPB for Analgesia in Total Hip Arthroplasty
Hip Osteoarthritis, Hip Arthropathy
RecruitingPhase 2
A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain
Osteoarthritis, Knee, Diabetic Neuropathic Pain
Recruiting
Marine Lipids Ease Painful TMD
Temporomandibular Disorder (TMD)
RecruitingPhase 2
A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis Pain
Osteoarthritis, Knee, Chronic Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Pnina Marom, M.P.H.; Ph.D. Student contact
Keren Sivan-Speier, M.D. principal investigator
Reuth Rehabilitation Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Group-based virtual Emotional Awareness & Expression Therapy - Hebrew (vEAET-H) in people with Chronic Musculoskeletal Pain and Cannabis Use, run by Reuth Rehabilitation Hospital at 1 site in Israel.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 28 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Shahar Lev-Ari, Ph.D. (+972-36407742, leva@tauex.tau.ac.il), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Brief Pain Inventory (BPI) - 4 items of pain severity (time frame: Pre-intervention (baseline), post-intervention (8 weeks after baseline), and follow-up (one month post-intervention)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07732062, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jul 2026.